Year Founded
2016
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Small molecule

PharmEnable General Information

Company uses AI and medicinal chemistry to develop complex small molecules with improved selectivity. Currently has pre-clinical oncology programs and partnerships for neurological diseases.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

No pipeline data available

For full access to PharmEnable's pipeline data

Book a demo

Key Partnerships

Sosei Heptares, Denali Therapeutics, LifeArc, Nxera

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

PharmEnable Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view PharmEnable's complete valuation and funding history, request access »

PharmEnable Investors

MP Healthcare Venture Management/Mitsubishi Tanabe Pharma Group venture arm
Investor Type: Venture Capital
Holding: Minority
Cambridge Enterprise Ventures/Funds VIII/Parkwalk Advisors
Investor Type: Venture Capital
Holding: Minority
Heyford Trust
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 9 investors. Get the full list »